跳至主要内容
临床试验/ISRCTN00586497
ISRCTN00586497已完成未知

Prospective, randomised, multicentre controlled trial on empiric antibiotic therapy in febrile neutropenic cancer patients: piperacillin and tazobactam plus tigecycline versus piperacillin or tazobactam monotherapy

niversity of Perugia (Italy)0 个研究点目标入组 390 人开始时间: 2012年7月17日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
390

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Consecutive adult (>18 age)
  • 2. Cancer patients were eligible for randomization if they had fever ((=38.5°C on one occasion or =38°C on two or more occasions within 12 hours)
  • 3. Chemotherapy-induced neutropenia (absolute neutrophils count less than 1000 per cubic millimeter anticipated to decrease to fewer than 500 cells per cubic millimeter within 24 to 48 hours) and a presumed infection
  • 4. Patients were enrolled only once in the study and were hospitalized at the participating centres

排除标准

  • 1. Had received any intravenous antibiotics during the preceding 96 hours
  • 2. Had a known allergy to any of the protocol antibiotics
  • 3. Had renal failure requiring hemo- or peritoneal dialysis or a serum creatinine level greater than 25 ml/min
  • 4. Were pregnant or had known human immunodeficiency virus infection

研究者

发起方
niversity of Perugia (Italy)

相似试验